Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Pemetrexed Dosing in NSCLC or Mesothelioma (IMPROVE-II)
NCT03655821Phase 4Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2019
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pemetrexed in non-small cell lung cancer (NSCLC) and mesothelioma (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Exposure (Area Under the Curve) at 24 hours and Fraction of patients with attainment of therapeutic exposure at 3 months. Started Feb 2019; status: terminated.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)mesothelioma
Beyond the preview
Go deeper on NCT03655821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655821.